Results 211 to 220 of about 232,812 (303)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam   +3 more
wiley   +1 more source

Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

open access: yesBlood Cancer Journal
Karan L. Chohan   +24 more
doaj   +1 more source

A prospective, phase IV study of ixazomib, pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

open access: yes
British Journal of Haematology, EarlyView.
Runfeng Zhang   +15 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

open access: yes
British Journal of Haematology, EarlyView.
Ahmed M. Elshazly   +5 more
wiley   +1 more source

MCL‐1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Myeloid cell leukaemia‐1 (MCL‐1) is an essential anti‐apoptotic protein and a promising therapeutic target in oncology. Early clinical studies of MCL‐1 inhibitors reported unexpected elevations in cardiac troponin, raising concerns about potential cardiotoxicity.
Markus B. Heckmann   +7 more
wiley   +1 more source

Plasmacytomas in Extramedullary Manifestation of Multiple Myeloma: A Case Report. [PDF]

open access: yesClin Med Insights Case Rep
Hmayed J   +6 more
europepmc   +1 more source

From infusion to pills in acute myeloid leukaemia: Reorganizing care beyond the infusion unit

open access: yes
British Journal of Haematology, EarlyView.
Fortunato Morabito   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy